Tradestie Institutional Equity Comparison Engine

LYRA vs NVCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NVCT Overall Edge

NVCT Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvectis Pharma, Inc. Common Stock (NVCT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus NVCT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NVCT sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
LYRA N/M vs NVCT N/M Fwd P/E
Growth & Margin Winner NVCT
Op Margin -25032.0% vs 0.0% ยท YoY -87.2% vs +0.0%
Momentum & Technical Winner NVCT
1Y -94.3% vs +216.8% ยท 52W Pos 1% vs 57%
Options & Structure Winner NVCT
UNCLASSIFIED (N/A IV) vs BREAKDOWN (9th %ile IV)
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.07
-0.21% 1D
Market Cap $696.0M
1M Return +0.69%
1Y Return +216.78%
Forward P/E N/M
Unified AI Score
53.4 / 100 HOLD
Tech 58.0 Fund 59.0 Flow 66.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LYRA -94.34% NVCT +216.78% Spread: +136.48 pp (NVCT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LYRA TTM Op. Margin: -25032.0% NVCT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs NVCT. Trailing 12-month operating profitability (LYRA -25032.0% vs NVCT 0.0%) and valuation multiples (LYRA N/M vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LYRA (0) vs NVCT (7)
Institutional Metric LYRA NVCT Criterion Row Winner
Market Capitalization Scale $2.3M $696.0M Larger Scale NVCT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -87.2% +0.0% Higher Growth NVCT
Operating Margin (TTM) Profitability -25032.0% 0.0% Higher Margin NVCT
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -404.5% -67.0% Higher ROE NVCT
52-Week Range Position Momentum 1% ($0โ€“$38) 57% ($6โ€“$29) Stronger Trend NVCT
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 248% Vol 0.70ฮฒ ยท 82% Vol Lower Realized Risk NVCT
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 53.4 / 100 (HOLD) Higher Composite NVCT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LYRA vs NVCT Buy Guide
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NVCT BREAKDOWN
99d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live NVCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LYRA nor NVCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.